Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (RNA-Seq).
RNA-seq (gene expression) · human · 33 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 33 samples: 10 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Co-targeting SOS1 enhances the antitumor effects of KRAS(G12C) inhibitors by addressing intrinsic and acquired resistanceNature cancer · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE225060_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA934578 and SRA study SRP422564. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 31 samples.
How we read this: 10 replicated groups read from 33 sample titles; they account for 31 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7038553 Before_treatment_wave1_NR1 Before_treatment_wave1_N
- GSM7038554 Before_treatment_wave1_NR2 Before_treatment_wave1_N
- GSM7038555 Before_treatment_wave1_NR3 Before_treatment_wave1_N
- GSM7038556 Before_treatment_wave1_NR4 Before_treatment_wave1_N
- GSM7038557 Before_treatment_wave1_NR5 Before_treatment_wave1_N
- GSM7038558 Before_treatment_wave1_NR6 Before_treatment_wave1_N
- GSM7038559 Relapse_wave1_A27 Relapse_wave1_A
- GSM7038560 Relapse_wave1_A29 Relapse_wave1_A
- GSM7038561 Relapse_wave1_C70
- GSM7038562 Relapse_wave1_D109 Relapse_wave1_D
- GSM7038563 Relapse_wave1_D112 Relapse_wave1_D
- GSM7038564 Relapse_wave1_D116 Relapse_wave1_D
- GSM7038565 Relapse_wave1_E137 Relapse_wave1_E
- GSM7038566 Relapse_wave1_E138 Relapse_wave1_E
- GSM7038567 Relapse_wave1_E149 Relapse_wave1_E
- GSM7038568 Relapse_wave1_F174 Relapse_wave1_F
- GSM7038569 Relapse_wave1_F178 Relapse_wave1_F
- GSM7038570 Relapse_wave1_G208
- GSM7038571 Relapse_wave1_I244 Relapse_wave1_I
- GSM7038572 Relapse_wave1_I261 Relapse_wave1_I
- GSM7038573 Relapse_wave1_J282 Relapse_wave1_J
- GSM7038574 Relapse_wave1_J294 Relapse_wave1_J
- GSM7038575 Adagrasib_Cetuximab_wave2_M61 Adagrasib_Cetuximab_wav…
- GSM7038576 Adagrasib_Cetuximab_wave2_M62 Adagrasib_Cetuximab_wav…
- GSM7038577 Adagrasib_Cetuximab_wave2_M63 Adagrasib_Cetuximab_wav…
- GSM7038578 Adagrasib_Cetuximab_wave2_M64 Adagrasib_Cetuximab_wav…
- GSM7038579 Adagrasib_BI3406_wave3_D13 Adagrasib_BI3406_wave3_D
- GSM7038580 Adagrasib_BI3406_wave3_D14 Adagrasib_BI3406_wave3_D
- GSM7038581 Adagrasib_BI3406_wave3_D16 Adagrasib_BI3406_wave3_D
- GSM7038582 Adagrasib_Cetuximab_wave3_M49 Adagrasib_Cetuximab_wav…
- GSM7038583 Adagrasib_Cetuximab_wave3_M50 Adagrasib_Cetuximab_wav…
- GSM7038584 Adagrasib_Cetuximab_wave3_M51 Adagrasib_Cetuximab_wav…
- GSM7038585 Adagrasib_Cetuximab_wave3_M52 Adagrasib_Cetuximab_wav…
- GSE286827 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy 87 samples shares combination, resistance, inhibitor
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares combination, inhibitor
- GSE339038 RNA-Seq of CD3+ T cells flow sorted from MLR assays with TNF/TNFR inhibitory compound combination treatments 64 samples shares combination, inhibitor
- GSE289619 IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non–small cell lung cancer II 32 samples shares interaction, resistance
- GSE273769 The PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. 24 samples shares combination, inhibitor
- GSE301688 Preclinical Evaluation of the Efficacy of a Cyclin-dependent Kinase Inhibitor Ribociclib in Combination with Letrozole Against Patient-Derived Glioblastoma Cells 18 samples shares combination, inhibitor
- GSE277035 Pre-clinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms (MPN) transformed to AML 10 samples shares combination, inhibitor
- GSE235863 T cell populations correlate with response and resistance to anti-PD-1 plus lenvatinib combination therapy in hepatocellular carcinoma 69 samples shares combination, resistance
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.